<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="0" size="8" family="BECFKA+TimesNewRomanPS" color="#000000"/>
	<fontspec id="1" size="8" family="BECFPE+TimesNewRomanPS" color="#000000"/>
	<fontspec id="2" size="8" family="BECGAG+TimesNewRomanPS" color="#000000"/>
	<fontspec id="3" size="13" family="BECGAG+TimesNewRomanPS" color="#000000"/>
	<fontspec id="4" size="10" family="BECGDJ+TimesNewRomanPSMT" color="#000000"/>
	<fontspec id="5" size="7" family="BECGDJ+TimesNewRomanPSMT" color="#000000"/>
	<fontspec id="6" size="9" family="BECFPE+TimesNewRomanPS" color="#000000"/>
	<fontspec id="7" size="8" family="BECGDJ+TimesNewRomanPSMT" color="#000000"/>
	<fontspec id="8" size="9" family="BECGAG+TimesNewRomanPS" color="#000000"/>
	<fontspec id="9" size="9" family="BECGDJ+TimesNewRomanPSMT" color="#000000"/>
	<fontspec id="10" size="6" family="BECGDJ+TimesNewRomanPSMT" color="#000000"/>
<text top="54" left="74" width="366" height="7" font="0"><i><b> Current </b></i></text>
<text top="54" left="271" width="66" height="7" font="0"><i><b>Neuropharmacology</b></i></text>
<text top="54" left="337" width="2" height="7" font="1"><i>,</i></text>
<text top="54" left="341" width="15" height="7" font="2"><b>2007</b></text>
<text top="54" left="356" width="2" height="7" font="1"><i>,</i></text>
<text top="54" left="358" width="6" height="7" font="0"><i><b> 5</b></i></text>
<text top="54" left="364" width="2" height="7" font="1"><i>,</i></text>
<text top="54" left="367" width="26" height="7" font="2"><b>157-167</b></text>
<text top="54" left="553" width="12" height="7" font="2"><b>157</b></text>
<text top="735" left="81" width="2" height="7" font="2"><b> </b></text>
<text top="735" left="229" width="83" height="7" font="2"><b>1570-159X/07 $50.00+.00 </b></text>
<text top="735" left="331" width="131" height="7" font="2"><b>©2007 Bentham Science Publishers Ltd.</b></text>
<text top="74" left="74" width="354" height="12" font="3"><b>Allosteric Modulation of Muscarinic Acetylcholine Receptors </b></text>
<text top="96" left="74" width="266" height="9" font="4">Karen J. Gregory, Patrick M. Sexton and Arthur Christopoulos</text>
<text top="94" left="339" width="3" height="6" font="5">*</text>
<text top="114" left="74" width="428" height="8" font="6"><i>Drug Discovery Biology Laboratory, Department of Pharmacology, Monash University, Clayton, Victoria, 3800, Australia </i></text>
<text top="129" left="114" width="31" height="7" font="2"><b>Abstract:</b></text>
<text top="129" left="145" width="393" height="7" font="7"> Muscarinic acetylcholine receptors (mAChRs) are prototypical Family A G protein coupled-receptors. The five mAChR sub-</text>
<text top="137" left="114" width="426" height="7" font="7">types are widespread throughout the periphery and the central nervous system and, accordingly, are widely involved in a variety of both </text>
<text top="146" left="114" width="426" height="7" font="7">physiological and pathophysiological processes. There currently remains an unmet need for better therapeutic agents that can selectively </text>
<text top="155" left="114" width="426" height="7" font="7">target a given mAChR subtype to the relative exclusion of others. The main reason for the lack of such selective mAChR ligands is the </text>
<text top="163" left="114" width="426" height="7" font="7">high sequence homology within the acetylcholine-binding site (orthosteric site) across all mAChRs. However, the mAChRs possess at </text>
<text top="172" left="114" width="427" height="7" font="7">least one, and likely two, extracellular allosteric binding sites that can recognize small molecule allosteric modulators to regulate the </text>
<text top="181" left="114" width="426" height="7" font="7">binding and function of orthosteric ligands. Extensive studies of prototypical mAChR modulators, such as gallamine and alcuronium, </text>
<text top="189" left="114" width="426" height="7" font="7">have provided strong pharmacological evidence, and associated structure-activity relationships (SAR), for a “common” allosteric site on </text>
<text top="198" left="114" width="424" height="7" font="7">all five mAChRs. These studies are also supported by mutagenesis experiments implicating the second extracellular loop and the inter-</text>
<text top="206" left="114" width="426" height="7" font="7">face between the third extracellular loop and the top of transmembrane domain 7 as contributing to the common allosteric site. Other </text>
<text top="215" left="114" width="424" height="7" font="7">studies are also delineating the pharmacology of a second allosteric site, recognized by compounds such as staurosporine. In addition, al-</text>
<text top="224" left="114" width="160" height="7" font="7">losteric agonists, such as McN-A-343, AC-42 and </text>
<text top="224" left="275" width="5" height="7" font="1"><i>N</i></text>
<text top="224" left="280" width="259" height="7" font="7">-desmethylclozapine, have also been identified. Current challenges to the field in-</text>
<text top="232" left="114" width="424" height="7" font="7">clude the ability to effectively detect and validate allosteric mechanisms, and to quantify allosteric effects on binding affinity and signal-</text>
<text top="241" left="114" width="151" height="7" font="7">ing efficacy to inform allosteric modulator SAR. </text>
<text top="256" left="74" width="47" height="7" font="8"><b>Key Words:</b></text>
<text top="256" left="121" width="449" height="8" font="9"> Acetylcholine, allosteric interaction, G protein-coupled receptor, molecular modeling, muscarinic acetylcholine receptor, </text>
<text top="265" left="74" width="293" height="8" font="9">mutagenesis, radioligand binding, structure-activity studies, ternary complex model. </text>
<text top="286" left="74" width="71" height="7" font="8"><b>INTRODUCTION </b></text>
<text top="300" left="74" width="2" height="8" font="9"> </text>
<text top="300" left="87" width="225" height="8" font="9">G protein-coupled receptors (GPCRs) account for 1 - 3% of the </text>
<text top="309" left="74" width="240" height="8" font="9">human genome, are abundantly expressed throughout the central </text>
<text top="319" left="74" width="236" height="8" font="9">nervous system (CNS) and periphery, and represent the major tar-</text>
<text top="328" left="74" width="239" height="8" font="9">gets for approximately 30% of all medicines on the world market. </text>
<text top="338" left="74" width="239" height="8" font="9">However, current CNS-based GPCR drug discovery has a higher </text>
<text top="348" left="74" width="239" height="8" font="9">than average attrition rate with respect to translating fundamental </text>
<text top="357" left="74" width="239" height="8" font="9">research to the clinic [41]; this is likely due to two reasons, namely, </text>
<text top="367" left="74" width="240" height="8" font="9">an insufficient mechanistic understanding of the complexities of </text>
<text top="376" left="74" width="236" height="8" font="9">CNS GPCR-mediated signaling and a lack of selective pharmacol-</text>
<text top="386" left="74" width="240" height="8" font="9">ogical tools for targeting therapeutically relevant GPCRs. As a </text>
<text top="396" left="74" width="238" height="8" font="9">consequence there are many GPCR-based drug discovery programs </text>
<text top="405" left="74" width="238" height="8" font="9">aiming to develop more selective compounds, both as tools to probe </text>
<text top="415" left="74" width="236" height="8" font="9">GPCR biology and also as potential therapeutic leads. The tradi-</text>
<text top="424" left="74" width="239" height="8" font="9">tional approach to GPCR-based drug discovery has been to focus </text>
<text top="434" left="74" width="240" height="8" font="9">on targeting that region of the receptor utilized by the receptor’s </text>
<text top="444" left="74" width="239" height="8" font="9">endogenous ligand, i.e., the “orthosteric” site [80]. However, it is </text>
<text top="453" left="74" width="236" height="8" font="9">now recognized that GPCRs possess topographically distinct, allos-</text>
<text top="463" left="74" width="236" height="8" font="9">teric binding sites, and that ligands that bind to these sites (allos-</text>
<text top="472" left="74" width="241" height="8" font="9">teric modulators) offer tremendous potential for more selective </text>
<text top="482" left="74" width="241" height="8" font="9">and/or effective therapies than conventional orthosteric ligands. </text>
<text top="492" left="74" width="239" height="8" font="9">This brief review will focus on one of the best-studied families of </text>
<text top="501" left="74" width="239" height="8" font="9">GPCRs with respect to the phenomenon of allosteric modulation, </text>
<text top="511" left="74" width="167" height="8" font="9">namely, the muscarinic acetylcholine receptors. </text>
<text top="524" left="74" width="240" height="7" font="8"><b>MUSCARINIC ACETYLCHOLINE RECEPTORS (mAChRs): </b></text>
<text top="534" left="74" width="88" height="7" font="8"><b>A BRIEF OVERVIEW </b></text>
<text top="547" left="74" width="2" height="8" font="9"> </text>
<text top="547" left="87" width="225" height="8" font="9">The mAChRs belong to the Family A (rhodopsin-like) subclass </text>
<text top="557" left="74" width="238" height="8" font="9">of GPCRs. Pharmacological and genetic studies have identified five </text>
<text top="567" left="74" width="136" height="8" font="9">distinct mAChR subtypes, classed M</text>
<text top="570" left="210" width="3" height="5" font="10">1</text>
<text top="567" left="213" width="10" height="8" font="9">-M</text>
<text top="570" left="223" width="3" height="5" font="10">5</text>
<text top="567" left="226" width="32" height="8" font="9">. The M</text>
<text top="570" left="258" width="3" height="5" font="10">1</text>
<text top="567" left="261" width="14" height="8" font="9">, M</text>
<text top="570" left="275" width="3" height="5" font="10">3</text>
<text top="567" left="278" width="29" height="8" font="9"> and M</text>
<text top="570" left="306" width="3" height="5" font="10">5</text>
<text top="576" left="74" width="144" height="8" font="9">subtypes preferentially couple to the G</text>
<text top="579" left="217" width="12" height="5" font="10">q/11 </text>
<text top="576" left="231" width="82" height="8" font="9">family of G proteins, </text>
<text top="586" left="74" width="236" height="8" font="9">resulting in phospholipase C activation, hydrolysis of inositol phos-</text>
<text top="595" left="74" width="149" height="8" font="9">phates and mobilization of intracellular Ca</text>
<text top="593" left="223" width="6" height="5" font="10">++</text>
<text top="595" left="229" width="83" height="8" font="9"> stores. In contrast, the </text>
<text top="605" left="74" width="8" height="8" font="9">M</text>
<text top="608" left="81" width="3" height="5" font="10">2</text>
<text top="605" left="84" width="28" height="8" font="9"> and M</text>
<text top="608" left="112" width="3" height="5" font="10">4</text>
<text top="605" left="115" width="194" height="8" font="9"> subtypes preferentially couple to the pertussis toxin-</text>
<text top="614" left="74" width="40" height="8" font="9">sensitive G</text>
<text top="618" left="114" width="8" height="5" font="10">i/o </text>
<text top="614" left="123" width="190" height="8" font="9">family of G proteins, resulting in the inhibition of </text>
<text top="624" left="74" width="239" height="8" font="9">adenylyl cyclase and subsequent cAMP formation. Although these </text>
<text top="634" left="74" width="239" height="8" font="9">generalizations speak to the best-characterized signaling pathways </text>
<text top="643" left="74" width="238" height="8" font="9">associated with the mAChRs, they should by no means be taken as </text>
<text top="653" left="74" width="236" height="8" font="9">absolutes. All five mAChR subtypes are known to couple pro-</text>
<text top="662" left="74" width="240" height="8" font="9">miscuously to multiple G proteins, usually in a cell background </text>
<text top="683" left="74" width="243" height="7" font="7">*Address correspondence to this author at NHMRC Senior Research  </text>
<text top="690" left="74" width="238" height="7" font="7">Fellow, Drug Discovery Biology Laboratory, Department of Pharmacology, </text>
<text top="698" left="74" width="240" height="7" font="7">Monash University, Clayton, 3800, Victoria, Australia; Tel: +613 9905 </text>
<text top="706" left="74" width="91" height="7" font="7">1146; Fax: +613 9905 5953;  </text>
<text top="713" left="74" width="155" height="7" font="7">E-mail: arthur.christopoulos@med.monash.edu.au</text>
<text top="286" left="330" width="239" height="8" font="9">dependent manner, and have been linked to additional intracellular </text>
<text top="296" left="330" width="238" height="8" font="9">pathways, including activation of mitogen activated protein kinases, </text>
<text top="305" left="330" width="239" height="8" font="9">Rho GTPases, nitric oxide synthases, multiple phospholipases, and </text>
<text top="315" left="330" width="239" height="8" font="9">the modulation of a variety of potassium, calcium and chloride ion </text>
<text top="325" left="330" width="51" height="8" font="9">channels [58]. </text>
<text top="338" left="330" width="3" height="8" font="9"> </text>
<text top="338" left="343" width="226" height="8" font="9">The mAChRs are widely distributed throughout the periphery </text>
<text top="348" left="330" width="239" height="8" font="9">and the CNS. Activation of peripheral mAChRs leads to increases </text>
<text top="357" left="330" width="240" height="8" font="9">in exocrine secretion, contraction of cardiac and smooth muscle </text>
<text top="367" left="330" width="238" height="8" font="9">(gastrointestinal tract and lungs), and reduced heart rate. Within the </text>
<text top="376" left="330" width="241" height="8" font="9">CNS, a far more complex array of physiological behaviors is </text>
<text top="386" left="330" width="236" height="8" font="9">thought to be mediated by the mAChRs, depending on their distri-</text>
<text top="396" left="330" width="114" height="8" font="9">bution and localization [13]. M</text>
<text top="399" left="444" width="3" height="5" font="10">1</text>
<text top="396" left="447" width="119" height="8" font="9"> mAChRs are predominantly ex-</text>
<text top="405" left="330" width="238" height="8" font="9">pressed post-synaptically in forebrain regions including the cerebral </text>
<text top="415" left="330" width="236" height="8" font="9">cortex, hippocampus and striatum [68, 69, 76, 80, 88]. These recep-</text>
<text top="424" left="330" width="240" height="8" font="9">tors have long been associated with cognitive deficits linked to </text>
<text top="434" left="330" width="239" height="8" font="9">neurodegenerative disorders, such as Alzheimer’s disease, and as </text>
<text top="444" left="330" width="115" height="8" font="9">such selective agonists of the M</text>
<text top="447" left="444" width="3" height="5" font="10">1</text>
<text top="444" left="447" width="121" height="8" font="9"> mAChR have been pursued as a </text>
<text top="453" left="330" width="239" height="8" font="9">potential avenue for treatment of dementia-related conditions [32]. </text>
<text top="463" left="330" width="23" height="8" font="9">The M</text>
<text top="466" left="353" width="3" height="5" font="10">2</text>
<text top="463" left="356" width="212" height="8" font="9"> mAChR is located pre-synaptically on both cholinergic and </text>
<text top="472" left="330" width="236" height="8" font="9">non-cholinergic neurons [30, 88] in the brainstem, hypothala-</text>
<text top="482" left="330" width="239" height="8" font="9">mus/thalamus, hippocampus, striatum and cortex [68, 69, 80], and </text>
<text top="492" left="330" width="236" height="8" font="9">generally serves an inhibitory function on the release of neuro-</text>
<text top="501" left="330" width="240" height="8" font="9">transmitters. It has been suggested that enhancing synaptic ACh </text>
<text top="511" left="330" width="118" height="8" font="9">levels by selectively inhibiting M</text>
<text top="514" left="448" width="3" height="5" font="10">2</text>
<text top="511" left="451" width="118" height="8" font="9"> autoreceptors may be beneficial </text>
<text top="520" left="330" width="236" height="8" font="9">in the treatment of psychosis and Alzheimer’s disease, and an at-</text>
<text top="530" left="330" width="240" height="8" font="9">tractive alternative to the currently used cholinesterase inhibitors </text>
<text top="540" left="330" width="104" height="8" font="9">for the latter disorder [20]. M</text>
<text top="543" left="434" width="3" height="5" font="10">3</text>
<text top="540" left="437" width="132" height="8" font="9"> mAChRs are expressed at relatively </text>
<text top="549" left="330" width="240" height="8" font="9">low levels in a number of regions including the cortex, striatum, </text>
<text top="559" left="330" width="240" height="8" font="9">hippocampus, hypothalamus/thalamus. These receptors have been </text>
<text top="568" left="330" width="202" height="8" font="9">particularly associated with appetite regulation, and the M</text>
<text top="572" left="532" width="3" height="5" font="10">3</text>
<text top="568" left="535" width="33" height="8" font="9"> receptor </text>
<text top="578" left="330" width="240" height="8" font="9">is currently a potential target for treatment of obesity and other </text>
<text top="588" left="330" width="146" height="8" font="9">metabolic disorders [7, 34, 69, 109]. M</text>
<text top="591" left="476" width="3" height="5" font="10">4</text>
<text top="588" left="479" width="86" height="8" font="9"> mAChRs are predomi-</text>
<text top="597" left="330" width="239" height="8" font="9">nantly found presynaptically in the striatum, hippocampus, cortex </text>
<text top="607" left="330" width="239" height="8" font="9">and hypothalamus/thalamus [9, 69, 80]. There is the potential that </text>
<text top="616" left="330" width="8" height="8" font="9">M</text>
<text top="620" left="337" width="3" height="5" font="10">4</text>
<text top="616" left="340" width="229" height="8" font="9"> mAChR selective antagonists may control tremor associated </text>
<text top="626" left="330" width="236" height="8" font="9">with Parkinson’s disease, whilst agonists may be developed as an-</text>
<text top="636" left="330" width="239" height="8" font="9">algesics, due to the regulation of neurotransmitter release in both </text>
<text top="645" left="330" width="240" height="8" font="9">cholinergic and non-cholinergic neurons [23, 113], and as novel </text>
<text top="655" left="330" width="240" height="8" font="9">antipsychotics, due to regulation of the dopaminergic system [1, </text>
<text top="664" left="330" width="53" height="8" font="9">91]. Finally, M</text>
<text top="668" left="383" width="3" height="5" font="10">5</text>
<text top="664" left="386" width="182" height="8" font="9"> mAChRs are discretely expressed at low levels in </text>
<text top="674" left="330" width="239" height="8" font="9">the brain, in particular in the ventral tegmental area [103, 110] as </text>
<text top="684" left="330" width="99" height="8" font="9">well as co-localised with D</text>
<text top="687" left="428" width="3" height="5" font="10">2</text>
<text top="684" left="431" width="137" height="8" font="9"> dopamine receptors in the substantia </text>
<text top="693" left="330" width="239" height="8" font="9">nigra pars compacta [107]. They are also implicated in the control </text>
<text top="703" left="330" width="184" height="8" font="9">of vasodilatation of cerebral blood vessels [108]. M</text>
<text top="706" left="514" width="3" height="5" font="10">5</text>
<text top="703" left="517" width="52" height="8" font="9"> mAChRs are </text>
<text top="712" left="330" width="236" height="8" font="9">associated with slow activation of dopaminergic neurons and sub-</text>
</page>
</pdf2xml>
